Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates

International Journal of Antimicrobial Agents

Volumn 36, Issue 5, 2010, Pages 415-419

  Campanile, Floriana ^a   Borbone, Sonia ^a   Perez, Marianna ^a   Bongiorno, Dafne ^a   Cafiso, Viviana ^a   Bertuccio, Taschia ^a   Purrello, Simona ^a   Nicolosi, Daria ^a   Scuderi, Cristina ^a   Stefani, Stefania ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Glycopeptides; HVISA; MIC creep; MRSA

Indexed keywords

DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; CONTROLLED STUDY; EPSILOMETER TEST; GENETIC SCREENING; HOSPITAL INFECTION; IN VITRO STUDY; INTERMETHOD COMPARISON; ITALY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; NONHUMAN; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; REGULATOR GENE; SENSITIVITY AND SPECIFICITY; SKIN INFECTION;

ANTI-BACTERIAL AGENTS; HUMANS; ITALY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCAL SKIN INFECTIONS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 77957671675     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.06.044     Document Type: Article

References (38)

1. Hiramatsu K., Hanaki H. Evaluation of reduced vancomycin susceptibility of MRSA strain Mu50 with various conditions of antibiotic susceptibility tests. Jpn J Antibiot 1997, 50:794-798. [in Japanese].
2. Appelbaum P.C. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007, 30:398-408.
3. Neoh H.M., Hori S., Komatsu M., Oguri T., Takeuchi F., Cui L., et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob 2007, 30:6-13.
4. Wootton M., MacGowan A.P., Walsh T.R., Howe R.A. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007, 45:329-332.
5. Howden B.P., Davies J.K., Johnson P.D., Stinear T.P., Grayson M.L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010, 23:99-139.
6. Charles P.G., Ward P.B., Johnson P.D., Howden B.P., Grayson M.L. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004, 38:448-451.
7. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
8. Soriano A., Marco F., Martínez J.A., Pisos E., Almela M., Dimova V.P., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
9. Maor Y., Hagin M., Belausov N., Keller N., Ben-David D., Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009, 199:619-624.
10. Pillai S.K., Wennersten C., Venkataraman L., Eliopoulos G.M., Moellering R.C., Karchmer A.W. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 2009, 49:1169-1174.
11. Wootton M., Howe R.A., Hillman R., Walsh T.R., Bennett P.M., MacGowan A.P. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001, 47:399-403. [Erratum in: J Antimicrob Chemother 2001;48:161].
12. Campanile F., Bongiorno D., Borbone S., Stefani S. Hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) in Italy. Ann Clin Microbiol Antimicrob 2009, 8:22.
13. Clinical and Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne PA: Clinical and Laboratory Standard Institute; 2009.
14. Fitzgibbon M.M., Rossney A.S., O'Connell B. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus. J Clin Microbiol 2007, 45:3263-3269.
15. Walsh T.R., Bolmström A., Qwärnström A., Ho P., Wootton M., Howe R.A., et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001, 39:2439-2444.
16. Cafiso V., Bertuccio T., Santagati M., Demelio V., Spina D., Nicoletti G., et al. agr-genotyping and transcriptional analysis of biofilm-producing Staphylococcus aureus. FEMS Immunol Med Microbiol 2007, 51:220-227.
17. Lodise T.P., Miller C.D., Graves J., Evans A., Graffunder E., Helmecke M., et al. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008, 62:1138-1141.
18. Lodise T.P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B.M., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
19. Rybak M.J., Leonard S.N., Rossi K.L., Cheung C.M., Sader H.S., Jones R.N. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008, 46:2950-2954.
20. Tenover F.C., Moellering R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretative criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44:1208-1215.
21. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007, 60:788-794.
22. Wang G., Hindler J.F., Ward K.W., Bruckner D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Antimicrob 2006, 44:3883-3886.
23. Robert J., Bismuth R., Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 2006, 57:506-510.
24. Alos J.I., Garcia-Hierro A., Rodriguez-Salvanes F. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 2008, 62:773-775.
25. Liu C., Chambers H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003, 47:3040-3045.
26. Renzoni A., Francois P., Li D., Felley W.L., Lew D.P., Vaudaux P., et al. Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004, 48:2958-2965.
27. Verdier I., Reverdy M.E., Etienne J., Lina G., Bes M., Vandenesch F. Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II. Antimicrob Agents Chemother 2004, 48:1024-1027.
28. Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:1079-1082.
29. Patel J.B., Jevitt L.A., Hageman J., McDonald L.C., Tenover F.C. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006, 42:1652-1653.
30. Wootton M., MacGowan A.P., Walsh T.R. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 2006, 50:4195-4197.
31. Rose W.E., Leonard S.N., Sakulas G., Kaatz G.W., Zevos M.J., Sheth A., et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008, 52:831-836.
32. Leonard S.N., Rybak M.J. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. J Antimicrob Chemother 2009, 63:155-160.
33. Akins R.L., Rybak M.J. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001, 45:454-459.
34. Borbone S., Campanile F., Bongiorno D., Perez M., Stefani S. Heteroresistance to glycopeptides in Italian methicillin-resistant Staphylococcus aureus isolates. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12-15 September 2009, San Francisco, CA 2009, ASM Press, Washington, DC, [Poster C2-114].
35. Howden B.P., Ward P.B., Charles P.G., Korman T.M., Fuller A., du Cros P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004, 38:521-528.
36. Huang Y.T., Liao C.H., Lee C.W., Hsueh P.R. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol 2008, 46:1132-1136.
37. Rybak M.J., Cappelletty D.M., Moldovan T., Aeschlimann J.R., Kaatz G.W. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998, 42:721-724.
38. Bowker K.E., Noel A.R., MacGowan A.P. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother 2006, 58:802-805.